A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1094-1100

  Yutani, Shigeru ^a   Komatsu, Nobukazu ^a   Yoshitomi, Munehiro ^a   Matsueda, Satoko ^a,b   Yonemoto, Koji ^c   Mine, Takashi ^a   Noguchi, Masanori ^b   Ishihara, Yuki ^a   Yamada, Akira ^b   Itoh, Kyogo ^a   Sasada, Tetsuro ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Medicine   (Japan)

^c KURUME UNIVERSITY   (Japan)

Author keywords

Chemotherapy resistant pancreatic cancer; IgG response; Overall survival; Personalized peptide vaccine

Indexed keywords

C REACTIVE PROTEIN; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IMMUNOGLOBULIN G; PEPTIDE EZH[2-735388]; PEPTIDE HNRPL 140; PEPTIDE HNRPL 501; PEPTIDE LCK 246; PEPTIDE LCK 422; PEPTIDE LCK 449; PEPTIDE LCK 486; PEPTIDE LCK 488; PEPTIDE LCK 90; PEPTIDE MRP[3-1293]; PEPTIDE PAP 213; PEPTIDE PAP 248; PEPTIDE PSA 248; PEPTIDE PSMA 624; PEPTIDE SART[2-161]; PEPTIDE SART[2-93]; PEPTIDE SART[3-109]; PEPTIDE SART[3-302]; PEPTIDE SART[3-503]; PEPTIDE SART[3-511]; PEPTIDE SART[3-734]; PEPTIDE VACCINE; PEPTIDE WHSC[2-103]; PEPTIDE WHSC[2-141]; SERUM AMYLOID A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMORAL IMMUNITY; HYPERGLYCEMIA; HYPOALBUMINEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OXONIC ACID; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; PROGNOSIS; SURVIVAL RATE; TEGAFUR; VACCINATION; YOUNG ADULT;

EID: 84880580190     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2556     Document Type: Article

References (15)

1. Kindler HL, Ioka T, Richel DJ, et al: Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 12: 256-262, 2011.
2. Okada T, Kamada T, Tsuji H, et al: Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS). J Radiat Res 51: 355-364, 2010.
3. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H and Saisho H: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94: 1575-1579, 2006.
4. Conroy T, Desseigne F, Ychou M, et al; Groupe Tumeurs Diges- tives of Unicancer and PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.
5. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007.
6. Pelzer U, Schwaner I, Stieler J, et al: Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III study from the German CONKO-study group. Eur J Cancer 47: 1676-1681, 2011.
7. Yanagimoto H, Mine T, Yamamoto K, et al: Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 98: 605-611, 2007.
8. Yanagimoto H, Shiomi H, Satoi S, et al: A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 24: 795-801, 2010.
9. Terasaki M, Shibui S, Narita Y, et al: Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 29: 337-344, 2011.
10. Terazaki Y, Yoshiyama K, Matsueda S, et al: Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. Cancer Sci 103: 638-644, 2012.
11. Noguchi M, Mine T, Komatsu N, et al: Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 10: 1266-1279, 2011.
12. Mine T, Sato Y, Noguchi M, et al: Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 10: 929-937, 2004.
13. Yamamoto K, Mine T, Katagiri K, et al: Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer. Oncol Rep 13: 874-883, 2005.
14. Lopez MN, Pereda C, Segal G, et al: Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 27: 945-952, 2009.
15. Firpo MA, Gay DZ, Granger SR, et al: Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg 33: 716-722, 2009. for Development of Innovative Research on Cancer Therapeutics (P-Direct)